TeleVenture et al. invest in APIM Therapeutics
TeleVenture, Sarsia Seed, Birk Venture and Ro Invest are said to have invested in Norwegian preclinical biotech company APIM Therapeutics.
TeleVenture invested through Norsk Innovasjonskapital III, according to reports. The company is said to be using the capital to advance its lead anti-cancer compound, ATX-101, towards late preclinical development. It previously received €440,000 from Sarsia Seed in June 2010.
Company
APIM Therapeutics is led by CEO Konstantinos Alevizopoulos and was established in 2009 at Prof M Otterlei's laboratory at the Norwegian University of Science and Technology (NTNU).
The company has identified a therapeutic intervention point for the treatment of a variety of cancer cells including bladder cancer and multiple myeloma.
More on Early-stage
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
L Catterton et al. in EUR 100m round for SellerX
SellerX has already raised amost EUR 250m in debt and equity in its 12 months since inception
Point72 Ventures leads €20m round for Curb
Food startup was founded in 2020 and will use the funding to invest in technology and its expansion in Stockholm
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds